A Pilot Open-Label Study Assessing the Effects of AHCC Supplementation on Lyme Disease Patients
Background: Lyme disease is the most commonly reported vector-borne illness in the United States. The disease is caused by the bacterium Borrelia burgdorferi and is transmitted to humans through the bite of infected ticks. Typical symptoms include fever, headache, fatigue, a skin rash, and joint pain. If left untreated, infection can spread to the joints, heart, and nervous system, resulting in inflammation and long-term symptoms that include arthritis and/or intermittent pain in joints and muscles, facial palsy, cardiovascular abnormalities and cognitive disturbances. Recent research suggests that late-stage Lyme disease may be a result of malfunctioning immune function. AHCCÒ is a natural immune modulating compound derived from a unique fraction of special cultured medicinal mushroom mycelia. Previous studies have also suggested that AHCCÒ exhibits preventive effect against a wide range of infections caused by MRSA, influenza and West Nile virus. The effect of AHCCÒ supplementation on Lyme disease patients was evaluated in the current study.
Methods: In a pilot open-label study, 12 Lyme disease patients were administered 3 grams of AHCCÒ daily for 8 weeks. Before commencement of the administration and after 4 and 8 weeks, the effects of AHCCÒ were evaluated clinically based on symptoms, serum antibodies to pathogens, inflammatory activity and serum immunological parameters. Patients completed questionnaires pertaining to Qualify of Life parameters.
Results: After 8 weeks of AHCCÒ administration, AHCCÒ ameliorated flu-like symptoms and manifestations in the eye, joint, muscle, nervous system and cardiovascular system. In addition, erythrocyte sedimentation rate, an index as inflammation and serum interleukin-8 was significantly decreased.
Conclusion: This study provides preliminary evidence that AHCCÒ may be effective in treating patients with Lyme disease.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.